[1] ZHU X D, HUANG C, SHEN Y H, et al.Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021,10(4):320-329.
[2] 中国抗癌协会肝癌专业委员会转化治疗协作组.肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志,2021,20(6):618-632.
[3] 蔡建强,赵宏,陈晓.肝癌综合治疗新格局[J].中华消化外科杂志, 2024,23(2):204-208.
[4] PARK JW,CHEN M,COLOMBO M,et al.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study[J]. Liver Int,2015,5(9):2155-2166.
[5] FINN R S,IKEDA M,ZHU A X,et al.Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol,2020,38(26):2960-2970.
[6] WANG K,GUO W X,CHEN M S,et al.Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale,multicenter,propensity mathching score analysis[J]. Medicine(Baltimore), 2016,95(11):e3015.
[7] AFFONSO B B, GALASTRI F L, DA MOTTA LEAL FILHO J M, et al. Long-term outcomes of hepatocellular carcinoma that under-went chemoembolization for bridging or downstaging[J]. World Gastroenterol, 2019,25(37):5687-5701.
[8] 赵海涛,桑新亭,芮静安,等.不能手术切除的晚期肝癌降期后切除疗效分析[J].中国医学科学院学报,2009,31(4):503-505.
[9] 中国医师协会肝癌专业委员会.肝细胞癌全程管理中国专家共识(2023版)[J].中华消化外科杂志, 2023,22(7):824-842.
[10] REN Z, FAN J, XU J, et al.LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma(ORIENT-32)[J]. Ann Oncol, 2020,31(Suppl):1287. |
